Close Menu

NEW YORK ─ AnchorDx said on Thursday that it has entered into a multi-year collaboration with the Lung Cancer Initiative at Johnson & Johnson to conduct a four-year study to enable the early detection and diagnosis of lung cancer. Specifically, the agreement is with Johnson & Johnson (China) Investment.

Investigators will enroll and track the progress of more than 3,000 patients with pulmonary nodules identified by computed tomography scanning, according to AnchorDx, a developer of next-generation sequencing-based early cancer detection and disease monitoring tests.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.